Apollo Therapeutics, a biopharmaceutical company focused on translating fundamental medical research into medicines through a hub-and-spoke approach, has closed $226.5 million in a Series C financing, led by lead investor Patient Square Capital. Financing significantly adds to the $195 million previously raised by the company, and to Apollo’s pipeline of over 20 programmes with multiple […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!